Sigyn Therapeutics, Inc.
SIGY· OTC
SIGYSigyn Therapeutics, Inc.
Filed Mar 21, 2022 · 10-K · 80 days after period end · 0001493152-22-007382
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 | Q4 2018dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | — | $5.34K | — |
| Net Income | -$1.23M | -$840.18K | -$1.55K | -$1.22M |
| EPS Diluted | — | — | $0.00 |
Sigyn Therapeutics, Inc. · CIK 1642159 · Engraved from SEC EDGAR
| — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2021 · filed Mar 21, 2022 · 80 d after period end
